TIMELINE
Actuate Therapeutics announces initiation of phase 2 clinical study in pancreatic cancer Actuate Therapeutics announces 9-ING-41 data presentation at ASCO Annual Meeting 2020 Actuate Therapeutics announces initiation of additional clinical studies for 9-ING-41. Actuate Therapeutics completes $6.5 million Series B-3 financing to expand clinical programs. Actuate Therapeutics completes $21.7 million Series B financing. (press release) Actuate Therapeutics opens Phase 1 / 2 Clinical Study of 9-ING-41 in Patients with Refractory Cancers. Dr. Torry Tucker presents research on the effect of 9-ING-41 in attenuating Idiopathic Pulmonary Fibrosis at the annual meeting of the American Thoracic Society. (poster) Dr. Li Ding presents research findings on GSK inhibition and 9-ING-41 synergizes with chemotherapy to inhibit pancreatic tumor growth in vivo at AACR Annual Meeting. (poster) Actuate Therapeutics announces FDA acceptance of IND application for 9-ING-41 and clearance to proceed with clinical study in patients with advanced cancers Actuate Therapeutics submits IND application for treatment of refractory cancers. Actuate Therapeutics receives rare pediatric disease designation for 9-ING-41 for treatment of neuroblastoma. FDA grants an additional Orphan Drug Designation for 9-ING-41 for the treatment of neuroblastoma. Actuate closes Series A Financing totaling $3.8M Dr. Matsangou presents research on GSK-3B and its role in head and neck carcinoma at the AACR meeting in Washington, DC. Actuate technologies featured in the Molecular Pathways special feature section in the journal Clinical Cancer Research. Dr. Francis J. Giles joins Actuate as Chief Medical Officer. (press release) FDA grants 9-ING-41 an Orphan Drug Designation for treatment of glioblastoma. Actuate receives a favorable FDA Written Response to our Pre-IND Plan for the development of 9-ING-41. The FDA laid out a very clear path on tasks necessary to complete in order to submit an IND, which sets the company up well for advancing 9-ING-41 into the clinic, and ultimately, to effectively treating patients. Actuate completes initial financing. Andrey Ugolkov presents his work the use of 9-ING-41 in treatment-sensitive and treatment-resistant glioblastoma at the Society of Neuro Oncology meeting. (see attachment) Actuate Forms Scientific Advisory Board License agreements are executed with both UIC and Northwestern for the technology and know-how that serves as the foundational intellectual property for Actuate Therapeutics. Company is incorporated as Apotheca Therapeutics, Inc, a Delaware C Corp, with Headquarters in Fort Worth, Texas.
July 31, 2020
(press release)
May 29, 2020
(press release)
(ATI 1801 Study)
April 9, 2020
(press release)
November 12, 2019
(press release)
May 14, 2019
December 17, 2018
(press release)
May 18, 2018
April 16, 2018
February 15, 2018
(press release)
January 15, 2018
(press release)
October 26, 2017
(press release)
August 18, 2017
June 17, 2017
April 3, 2017
(poster)
March 31, 2017
March 1, 2017
March 29, 2016
December 18, 2015
December 11, 2015
November 19, 2015
October 29, 2015
April 16, 2015
Jan 16, 2015